CD74 level predicts immunotherapy response in bowel cancer
The amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy, new research has revealed.
If integrated into the clinic, the researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, say testing for this protein could potentially allow hundreds of previously ineligible patients to benefit from the treatment.
In a study published in Cancer Cell, the researchers investigated why immunotherapy only works for certain people with bowel cancer, and how we might increase the number of patients who can benefit from this treatment.
The team first studied tumour samples from both subtypes, and from people who responded to immunotherapy drugs versus people who didn’t. They found that three types of immune cells needed to be present for the tumour to respond to treatment: T and NK cells and macrophages.
When all three were present, the T cells produced interferons, which triggered a signal in macrophages and tumour cells. This signal was much higher in tumours of the deficient subtype that responded to immunotherapy, but, surprisingly, some patients in the proficient subtype also produced a comparable signal, suggesting that their immune system may be in the right state to benefit from immunotherapy.
Findings from spatial transcriptomics
Using spatial transcriptomics, the team observed that T cells stimulated nearby macrophages and tumour cells to produce a protein called CD74 and that tumours that were responding to immunotherapy drugs produced higher levels of CD74.
The researchers also studied samples from several international clinical trials testing immunotherapy in groups of people with the proficient subtype. They found that people who responded to immunotherapy had significantly higher levels of CD74 than those who did not respond.
Francesca Ciccarelli, Principal Group Leader of the Cancer Systems Biology Laboratory at the Crick, and Professor of Cancer Genomics at Queen Mary University of London’s Barts Cancer Institute, said: “Our work suggests that testing for CD74 levels – which signal that the immune system is ‘just right’ to fight the tumour – could widen access to immunotherapy. This could revolutionise treatment for a sizeable fraction of people with the proficient bowel cancer subtype, which is a large number of patients across the UK in real terms. It could also be used to identify people with the deficient subtype who won’t respond, saving them from experiencing side effects unnecessarily.”
Diana Spencer, Senior Digital Content Editor, DDW
